Bexsero is a vaccine designed to protect against invasive meningococcal disease caused by Neisseria meningitidis serogroup B. It's approved for use in individuals aged 10 through 25 years. In other words, Bexsero helps your body build immunity to a specific type of meningitis.
Understanding Meningococcal Disease and Bexsero
Meningococcal disease, particularly that caused by serogroup B Neisseria meningitidis, can lead to severe complications. Bexsero offers active immunization, meaning it stimulates your body's immune system to produce antibodies that can fight off this specific bacterial infection.
Key Features of Bexsero
- Target Audience: Approved for individuals aged 10-25.
- Protection Against: Invasive disease caused by Neisseria meningitidis serogroup B.
- Mechanism: Active immunization – stimulates the body's immune system.
Why is Bexsero Important?
Meningococcal disease can be life-threatening, and vaccination is a crucial preventative measure. Bexsero targets a specific serogroup (B) of the bacteria responsible for the disease, providing targeted protection for those within the approved age range.
